Not that I'm here to defend the FDA, but I certainly don't
Not that I'm here to defend the FDA, but I certainly don't envy them. We are a bit partial because we typically follow cydy religiously(guilty as charged) however note the number of urls posted containing news stories listing a host of other drugs. They have to sift through all that chaffe and figure out fact from fiction with endless biotechs in their ear. If they get it wrong and approve a drug that doesn't work with unknown side effects, they'll be mocked in the court of public opinion and lose trust for other drug approvals AND we lose more covid patients to an ineffective treatment. If they don't approve a drug that we later find out does work, they didn't move fast enough because we have the benefit of hindsight and we'll have lost more covid patients. It's almost a lose lose situation because in the public eye/perfect world they should have had a drug ready before the pandemic and now it's here and they can't move fast enough.
They are under the microscope like never before. I'm glad we do have some sort of organization to help separate the contenders from the pretenders.
I'm sure no one wants to hear anything positive about the FDA but I'm looking at it from their side and how many big pharmas are probably in their ear, plus the president, and the media pushing them to just let everything through even if it might be snake oil.
My hope is the data cydy provides gives some clarity that leronlimab is the real deal. I don't doubt there are people in the FDA who know someone or somebody affected by covid and want a drug to help as much as we do and sense an urgency.
I'm ok if this post gets removed. Just thought I would throw out a different perspective even if it's a bit contrarian.
11
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Introduction Operating a business in a high-risk industry presents unique challenges, particularly when it comes to payment processing. Financial institutions and payment gateways often categorize businesses as high-risk for reasons such as high chargeback potential, international sales, or complex regulatory requirements. For this reason, specialized solutions...
Continue Reading
Hyundai's Recent Vehicle Recall Hyundai Motor Company has announced a significant recall affecting over 226,000 vehicles across the United States. This action stems from concerns regarding the rear view camera, which has been found to potentially fail in displaying the camera image. The National Highway Traffic Safety Administration (NHTSA) released this information,...
Continue Reading
Revolutionizing Power Solutions for Data Centers As the demand for data centers continues to surge, it's essential for these facilities to harness cutting-edge power solutions to ensure reliability and sustainability. Recent discussions have highlighted the pivotal role of advanced engine technology in meeting energy needs while minimizing environmental impacts. This...
Continue Reading
Shell Plc Reports Strong Earnings Shell Plc (NYSE: SHEL) has recently revealed its financial performance, which showcased a blend of positive earnings yet slightly disappointing revenue figures. This outcome has led to a rise in their shares, as investors digest the results and the implications for the company moving forward. Performance Breakdown The adjusted earnings...
Continue Reading
Banijay Group's Share Transactions Overview Banijay Group N.V. (894500G73K46H93RF180) is revealing its latest transactions involving company shares, showcasing the trading activities conducted within the recent week. These disclose the transactions made from December 8 to December 12, following the green light granted during the recent shareholder meeting. This...
Continue Reading